Novosense
- Company typePrivate
- Founded2004
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Novosense firmographics
Firmographics- Name
- Novosense
- Legal name
- Novosense AB
- Website
- https://novosense.se
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Novosense industry classification
Industry- Product category
- Wireless ECG Monitoring Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
Keywords
Where Novosense is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Novosense business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- CardioSenseSystem Product Sales: Novosense sells its CardioSenseSystem including CardioPatch sensors (single-use disposable), Access Points (multi-use), Server Software, and Information Centre monitoring software. The business model combines hardware sales (sensors, access points) with software licensing.
- CardioPatch Sensor Consumables: Single-use CardioPatch sensors represent recurring consumable revenue. Each sensor operates for 48 hours and is replaced, creating a recurring revenue stream tied to patient monitoring hours.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | CardioSenseSystem product line - pricing not publicly disclosed |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Novosense product offering
Product offeringCore offering
Novosense designs, manufactures, and sells the CardioSenseSystem, a CE-certified cable-free continuous ECG monitoring system for hospitals. The system bundles single-use self-adhesive CardioPatch wireless sensors (48-hour operation), multi-use Access Point receivers, Server Software, and Information Centre monitoring software, enabling AI-driven arrhythmia detection with no cables, no sterilization, and reduced false alarms.
Product overview
Novosense offers a unified ECG monitoring platform called CardioSenseSystem®, consisting of three smart patches (CardioPatch® sensors), a multi-use Access Point, Server Software, and Information Centre monitoring software. The system operates as a complete cable-free ECG monitoring solution where CardioPatch sensors continuously transmit ECG data to the Access Point, which relays information to the Server Software for storage and processing, displayed through the Information Centre for clinical staff monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- CardioSenseSystem®: CE-certified AI-enhanced ECG monitoring system consisting of CardioPatch sensors, Access Point, server software, and Information Centre monitoring software.
- CardioPatch®
- Novosense Access Point
- SafeNovo®
Products and services
- CardioSenseSystem CE-certified (MDR No. 766007) cable-free, AI-enhanced continuous ECG monitoring system for hospital cardiac care, intensive care, and operating theatres. Combines single-use CardioPatch sensors, multi-use Access Point, Server Software, and Information Centre monitoring software into one platform for clinical staff.
- CardioPatch Wireless, self-adhesive single-use ECG sensor applied to the body like a traditional electrode. Operates 48 hours, defibrillation-proof, waterproof, with 1000 Hz sampling frequency and automatic activation on removal from tray. For hospital ECG monitoring in adult patients.
- Novosense Access Point Multi-use high-capacity radio receiver that collects wireless ECG data from up to 16 patients (up to 80 CardioPatches) simultaneously and relays the information to the server. Also designed to receive data from pulse oximeters, blood pressure sensors, and respiratory sensors.
- Novosense Server Software Server software that calculates and stores ECG data in an SQL database and broadcasts information to the Information Centre. Configurable to support up to 255 Information Centre clients simultaneously. Used by hospital IT and clinical engineering teams.
- Novosense Information Centre Monitoring software that continuously displays patient ECG curves with audio and visual alarms for critical events. Monitors up to 16 patients simultaneously, supports dual screens, and analyzes trends, alarms, curves, and ST segments for clinical staff at nursing stations.
Quantifiable outcome
- 30× higher sensitivity: 364 vs 12 critical alarms (p < 0.0001)
- +7 more outcomes
Companies that use Novosense
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Novosense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Novosense partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- EU Horizon ICT Programme ConsortiumcoreNovosense and partners awarded €4 million in EU Horizon ICT programme for SmartVista project. Partners include Tyndall National Institute, Fraunhof-EMFT, CNRS, UCC, Analog Devices, and Novosense. The goal is to develop a smart cardiac monitoring patch powered by body heat for digital healthcare.
- SmartVista Project Partners (Tyndall, Fraunhof-EMFT, CNRS, UCC, Analog Devices)coreEU Horizon project developing self-powered cardiac monitoring device using 1D/2D nanomaterial-based sensors, thermoelectric energy harvesters, and printable battery systems. Project positions Novosense at forefront of digital health and wearable biosensor technology.
- VitalHomeHealthCare Project ConsortiumminorEurostars project to develop miniaturized self-contained wireless wearable sensor for home health care vital signs monitoring. Primary vital signs are breathing and ECG. UWB radar technology used for breathing monitoring implemented on single CMOS chip.
- NextGenECG ProjectminorEurostars project developing cable-free ECG monitoring system consisting of ECG sensor, ECG base station, and back-end ECG system. Novel technology enables ECG monitoring without cables attached to the body.
- Acreo ABminorFounding research collaborator in the establishment of Novosense AB as a research collaboration between Acreo AB, Tilly Medical AB, and Fredrik Sebelius (Lund University).
- Tilly Medical ABminorFounding research collaborator in the establishment of Novosense AB as a research collaboration between Acreo AB, Tilly Medical AB, and Fredrik Sebelius (Lund University).
- Lund UniversityminorAcademic founding research collaborator through Fredrik Sebelius in the establishment of Novosense AB. Company maintains close cooperation with Lund University, the largest university in Scandinavia, located at Ideon Science Park.
- Thoracic Surgery Department, Lund, SwedencoreClinical trial site for CardioSenseSystem comparative study. Department has well-documented expertise in heart surgery and is one of two places in Sweden that carry out heart transplantation. Study sponsored by Novosense AB.
- The Swedish Institute for Health Economics (IHE)coreConducted health economic study of CardioSenseSystem at Skåne University Hospital, demonstrating cost advantages including 65-85% reduction in acquisition costs and 76-79% reduction in staff costs.
- Skåne University HospitalcoreHealth economic study site for CardioSenseSystem including four inpatient wards. Study demonstrated superior performance and significant cost reductions compared to existing ECG systems.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Novosense competitors and assessment
Company assessmentEmerging players
- VivaLNK: VivaLNK makes wearable medical sensors and continuous vital-sign patches for both clinical and remote patient monitoring. It overlaps with Novosense's wireless patch technology but focuses more on RPM platforms and partners rather than direct hospital sales.
Broad incumbents
- GE HealthCare (Patient Monitoring): GE HealthCare offers CARESCAPE and bedside ECG/telemetry systems serving the same ICU and step-down unit customers as Novosense. It is a broad incumbent whose monitoring business sits alongside imaging, ultrasound, and pharmaceuticals.
- Hillrom (now part of Baxter): Hillrom (acquired by Baxter) offered connected bed and vital-sign monitoring solutions in hospital settings, overlapping with Novosense's patient monitoring focus. As a broad incumbent, it competes across multiple care delivery touchpoints.
- Dräger (Infinity Patient Monitoring): Dräger's Infinity patient monitoring platform is widely deployed in European hospitals for ICU and peri-operative ECG monitoring, directly competing with Novosense's cable-free approach. Dräger is a broader acute-care-focused medtech incumbent.
- Nihon Kohden: Nihon Kohden is a Japanese medtech company whose patient monitoring and ECG product lines serve hospitals globally, including European ICUs. It is a direct functional competitor to Novosense's CardioSenseSystem.
- Philips (Patient Monitoring): Philips is a global leader in hospital patient monitoring with bedside telemetry and IntelliVue ECG systems used in ICUs and cardiac care units. It competes with Novosense in the same hospital ECG monitoring category but as part of a much broader portfolio including imaging and informatics.
- Mindray (BeneVision): Mindray's BeneVision patient monitoring system targets the same hospital ICU and cardiac care units as Novosense with multi-parameter bedside monitors. It is a Chinese-headquartered incumbent that has expanded aggressively in Europe.
Direct peers
- Boston Scientific / Preventice (BodyGuardian): Boston Scientific (via its Preventice acquisition) offers the BodyGuardian family of wearable cardiac sensors for continuous ECG and remote monitoring. It competes directly with Novosense in the wireless ambulatory/in-hospital ECG patch category.
- iRhythm Technologies (Zio): iRhythm's Zio patch is a wearable, single-use continuous ECG monitor that directly competes with Novosense's CardioPatch on cable-free, long-duration cardiac monitoring. While iRhythm is primarily US-focused on ambulatory diagnostics, the core patch-based technology and use case are highly comparable.
- Spacelabs Healthcare (Patient Monitoring): Spacelabs Healthcare provides bedside and telemetry ECG monitoring systems for hospitals, overlapping directly with Novosense's target ICU and step-down unit customers. It is a more focused, mid-size patient monitoring specialist compared to the broad incumbents.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Novosense social profiles
Digital presenceNovosense compliance and trust
Trust signalCompliance1 record
Novosense financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novosense leadership team
Management profileNumber of profiles
Profiles2 records
Novosense funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novosense M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novosense
What does Novosense do?
Novosense designs, manufactures, and sells the CardioSenseSystem, a CE-certified cable-free continuous ECG monitoring system for hospitals. The system bundles single-use self-adhesive CardioPatch wireless sensors (48-hour operation), multi-use Access Point receivers, Server Software, and Information Centre monitoring software, enabling AI-driven arrhythmia detection with no cables, no sterilization, and reduced false alarms.
Is Novosense a public or private company?
Novosense is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Novosense founded?
Novosense was founded in 2004. It employs 1 to 10 people.
Where is Novosense based?
Novosense is headquartered in Lund, Sweden, in the Europe region.
How does Novosense make money?
Two revenue lines are on record. CardioSenseSystem Product Sales are the primary driver. The others are cardioPatch Sensor Consumables.
Who are Novosense's main competitors?
VivaLNK is listed as an emerging player. Broad incumbents are GE HealthCare (Patient Monitoring), Hillrom (now part of Baxter), Dräger (Infinity Patient Monitoring), Nihon Kohden, Philips (Patient Monitoring) and Mindray (BeneVision). Direct peers are Boston Scientific / Preventice (BodyGuardian), iRhythm Technologies (Zio) and Spacelabs Healthcare (Patient Monitoring).
Does Novosense have an API?
No public API is recorded for Novosense.
What industry is Novosense in?
Novosense's product category is Wireless ECG Monitoring Systems. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.